Market Overview

Global Conjugate Vaccine Market Analysis & Forecasts 2018-2023, With an Expected CAGR of 14.6% -


The "Global
Conjugate Vaccine Market (2018-2023)"
report has been added to's

Conjugate vaccine is a type of vaccine that contains bacterial capsular
polysaccharide, attached to a protein to enhance immunogenicity and
protect against invasive diseases. The global conjugate vaccine market
is expected to grow at a CAGR of 14.6%, leading to a global revenue of
USD 100.59 Bn by 2023. By volume, it is anticipated to reach 9600.56
Million units by 2023, expanding at a CAGR of 17.2%.

The conjugate vaccine market is classified into two primary
segments-based on disease indication: pneumococcal, haemophilus
influenza type b, diphtheria-tetanus-pertussis, meningococcal and
others; and based on end user: paediatric and adult. Asia-Pacific will
have the highest CAGR during the forecasted period.

Key growth factors:

  • Rising adoption of cancer therapeutic vaccines, improvement in patient
    compliance along with an increasing product pipeline, and growing
    efforts for the adoption of appropriate preventive screening methods
    to help avert adverse reactions will accelerate the market.
  • Conjugate Vaccine market is expected to have positive growth owing to
    technological advancements, growth initiatives for the production of
    low-cost vaccines, and widespread routine vaccination programs in
    emerging economies.

Threats and key players:

  • Although the conjugate vaccine market is expected to have a positive
    growth globally, lack of awareness, shortage risk, the situation of
    oligopoly, uncertainty about the future of international initiatives,
    emerging manufacturers, and costs and prices of new vaccines will
    hinder growth.
  • Major Conjugate Vaccine providers operating in the market are
    GlaxoSmithKline, Pfizer Inc., Sanofi Pasteur, Novartis, etc.

Companies Mentioned

  • GlaxoSmithKline
  • Pfizer Inc.
  • Merck & Co.
  • Novartis
  • Sanofi Pasteur
  • CSL Limited
  • Bharat Biotech International
  • Biological E Limited
  • Serum Institute of India

Key Topics Covered:

Chapter 1: Executive summary

Chapter 2: Market overview

Chapter 3: Major segment overview - global by disease indication

Chapter 4: Major segment overview - global by end user

Chapter 5: North America - by disease indication

Chapter 6: North America - by end user

Chapter 7: Europe - by disease indication

Chapter 8: Europe - by end user

Chapter 9: Asia Pacific - by disease indication

Chapter 10: Asia Pacific - by end user

Chapter 11: Latin America - by disease indication

Chapter 12: Latin America - by end user

Chapter 13: Middle East & Africa - by disease indication

Chapter 14: Middle East & Africa - by end user

Chapter 15: Competitive landscape

Chapter 16. Appendix

For more information about this report visit

View Comments and Join the Discussion!